Paul Mouncey
@paulmouncey.bsky.social
Researcher in critical care. Co-Director at Intensive Care National Audit & Research Centre.
Reposted by Paul Mouncey
Conservative oxygen therapy with a target SpO2 of 90% did not reduce 90-day all-cause mortality compared to usual oxygen therapy in mechanically ventilated adult patients.
#CCR25 @criticalcarereviews.com
ja.ma/4mZgVl6
#CCR25 @criticalcarereviews.com
ja.ma/4mZgVl6
June 13, 2025 at 4:52 PM
Conservative oxygen therapy with a target SpO2 of 90% did not reduce 90-day all-cause mortality compared to usual oxygen therapy in mechanically ventilated adult patients.
#CCR25 @criticalcarereviews.com
ja.ma/4mZgVl6
#CCR25 @criticalcarereviews.com
ja.ma/4mZgVl6
Reposted by Paul Mouncey
Editorial: The UK-ROX trial demonstrates that targeting lower oxygen saturation in critically ill patients is safe but does not improve outcomes.
#CCR25 @criticalcarereviews.com
ja.ma/3FxWhYu
#CCR25 @criticalcarereviews.com
ja.ma/3FxWhYu
June 13, 2025 at 4:52 PM
Editorial: The UK-ROX trial demonstrates that targeting lower oxygen saturation in critically ill patients is safe but does not improve outcomes.
#CCR25 @criticalcarereviews.com
ja.ma/3FxWhYu
#CCR25 @criticalcarereviews.com
ja.ma/3FxWhYu